RVL Pharmaceuticals is solely dedicated to bringing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% to market and enhancing patient care. Born out of the eye care community, Upneeq® is the first and only FDA-approved prescription treatment for acquired ptosis in adults, and represents a significant advancement for practitioners and their patients. Upneeq® is available exclusively through RVL’s fully-owned and integrated pharmacy that was designed to modernize prescription access through a consistent and seamless experience from Rx to fulfillment for provider and patient.